Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the protocol is to demonstrate the safety and the efficacy of a single
injection of a new formulation of Clostridium Botulinum toxin type A haemagglutinin complex
(BTX A HAC NG) to improve the appearance of moderate to severe glabellar lines (the lines
between the eyebrows) and to assess the long term efficacy and safety of BTX-A-HAC NG after
repeated injections.
Phase:
Phase 3
Details
Lead Sponsor:
Ipsen
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA